Key facts
- It has raised $310.0M across 5 recorded rounds; the latest was Later Stage VC (Series E) ($150.0M) in May 2023.
- Carmot Therapeutics has filed 6 Form Ds with the SEC since 2010, most recently Jun 2023 ($150.0M sold to 25 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 5 rounds
- ·Watchlist + deal alerts for Carmot Therapeutics
Create free account
No card required
Funding rounds
5 roundsMay 2023Later Stage VC (Series E)$150.0M▮
Jul 2022Later Stage VC (Series D)$160.0M▮
About Carmot Therapeutics
- Industry
- Biotechnology
PA Mark — not yet priced
Carmot Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Carmot Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Carmot Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.